# Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy

> **NCT01827553** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 830 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Induction chemotherapy with gemcitabine or FOLFIRINOX
- **RADIATION:** Radiotherapy, 28 x 1.8 Gy
- **DRUG:** Chemotherapy, gemcitabine
- **DRUG:** Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy

## Key facts

- **NCT ID:** NCT01827553
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-04
- **Primary completion:** 2021-02-02
- **Final completion:** 2023-11-08
- **Target enrollment:** 830 (ESTIMATED)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827553, "Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01827553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*